I see reports of neutralizing antibodies in aesthetic application too.
An immune response rate that is sufficiently lower than the competition will pay dividends down the road if it is demonstrable. I don't see value right now. I also don't see value to the 'yuck factor' if they are already willing to be injected with a botulism toxin.
What would be interesting to know is if 002 is enough different from other strains to be able to treat some number of treatment failures from those strains.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.